| P50 | author | Florent Malard | Q60374032 |
| | Xiao-Jun Huang | Q57008355 |
| P2093 | author name string | Joycelyn P Y Sim | |
| P2860 | cites work | Secondary treatment of acute graft-versus-host disease: a critical review | Q26823275 |
| | Advances in predicting acute GVHD | Q27021123 |
| | Acute graft-versus-host disease: a bench-to-bedside update | Q27687130 |
| | Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease | Q28272414 |
| | A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease | Q28274509 |
| | International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. | Q30994673 |
| | Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept | Q33213561 |
| | Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients | Q33440405 |
| | High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. | Q33950015 |
| | Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation | Q34184622 |
| | Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD. | Q34441886 |
| | National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report | Q34474243 |
| | Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond | Q34616147 |
| | A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality | Q35177453 |
| | Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial | Q35669901 |
| | Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR | Q35848083 |
| | Combination antithymocyte globulin and soluble TNFα inhibitor (etanercept) +/− mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease | Q57252632 |
| | Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease With Fecal Microbiota Transplantation: A Pilot Study | Q57492011 |
| | Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease | Q57790339 |
| | Phase I/II trial of a combination of anti-CD3/CD7 immunotoxins for steroid-refractory acute graft-versus-host disease | Q58613506 |
| | The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial | Q58793818 |
| | Steroid-Refractory Acute GVHD: Lack of Long-Term Improved Survival Using New Generation Anticytokine Treatment | Q58814216 |
| | Fecal microbiota transplantation with frozen capsules for a patient with refractory acute gut graft-versus-host disease | Q59333338 |
| | Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) | Q59336540 |
| | Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD | Q60907227 |
| | Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation | Q80177840 |
| | Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease | Q80290661 |
| | Anti-tumor necrosis factor-a for the treatment of steroid-refractory acute graft-versus-host disease | Q80830121 |
| | Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies | Q81322985 |
| | Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience | Q82270549 |
| | Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist | Q82975055 |
| | Graft-versus-host disease | Q83468020 |
| | Diagnosis and management of acute graft-versus-host disease | Q83992372 |
| | Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease | Q84335656 |
| | Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment | Q87414996 |
| | Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 |
| | Lessons Learned from Early Experiences with Vedolizumab for Steroid-Refractory Acute Graft- versus-Host Disease with Gastrointestinal Involvement | Q88229472 |
| | High gastrointestinal microbial diversity and clinical outcome in graft-versus-host disease patients | Q89108835 |
| | Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label, phase 2 trial | Q90237307 |
| | Basiliximab as Treatment for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients after Haploidentical Hematopoietic Stem Cell Transplantation | Q91196017 |
| | Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib | Q91587430 |
| | Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation | Q92023470 |
| | First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation | Q36113205 |
| | Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | Q36862931 |
| | Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease | Q36873427 |
| | Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion | Q37154179 |
| | Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. | Q37376599 |
| | Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease | Q37552088 |
| | Extracorporeal Photopheresis for Second-Line Treatment of Chronic Graft-versus-Host Diseases: Results from a Health Technology Assessment in Italy. | Q38532284 |
| | The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD. | Q38610904 |
| | Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation | Q38616695 |
| | Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. | Q38684871 |
| | Mesenchymal stromal cells and immunomodulation: A gathering of regulatory immune cells | Q38705808 |
| | Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease | Q38803321 |
| | Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study. | Q38839140 |
| | Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival | Q39977675 |
| | Telomere shortening in enterocytes of patients with uncontrolled acute intestinal graft-versus-host disease | Q40408857 |
| | A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. | Q40430861 |
| | Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. | Q40551837 |
| | Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease | Q40991233 |
| | Response-guided therapy for steroid-refractory acute GVHD starting with very-low-dose antithymocyte globulin | Q41547054 |
| | ATG plus corticosteroid therapy for acute graft-versus-host disease: predictors of response and survival | Q41606846 |
| | Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft-versus-host-disease | Q42336324 |
| | Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab | Q44092412 |
| | A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease | Q44387571 |
| | Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis | Q44791854 |
| | Daclizumab has poor efficacy in steroid-refractory severe acute graft-versus-host disease: a single centre experience with 12 allograft patients | Q46890995 |
| | Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience | Q47137561 |
| | Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival. | Q48120485 |
| | Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). | Q48146759 |
| | Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission. | Q48359012 |
| | The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. | Q49384876 |
| | Biomarkers in Graft-Versus-Host Disease: from Prediction and Diagnosis to Insights into Complex Graft/Host Interactions | Q49505570 |
| | Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy | Q49679320 |
| | Vedolizumab for treatment of steroid-refractory lower gastrointestinal acute graft-versus-host disease | Q49679562 |
| | α1-Antitrypsin Infusion for treatment of Steroid Resistant Acute Graft-versus-Host Disease | Q50044411 |
| | Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials | Q50115590 |
| | Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. | Q50798708 |
| | Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation. | Q50847625 |
| | Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation. | Q51025819 |
| | Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. | Q51036325 |
| | Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells. | Q51582063 |
| | Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. | Q52937162 |
| | Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. | Q52953976 |
| | Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease. | Q52994863 |
| | Prognosis of grade 3-4 acute GVHD continues to be dismal. | Q53110668 |
| | Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody. | Q53812212 |
| P577 | publication date | 2020-04-03 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Treatment and unmet needs in steroid-refractory acute graft-versus-host disease | |